Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
The Schepens Eye Research Institute Inc. has 5 pending office actions in Biotechnology & Pharmaceuticals. Those matters are distributed among 5 distinct examiners and 5 distinct art units, indicating a portfolio with multiple examination channels rather than a single point of contact.
DAVIS, BRIAN J is the busiest examiner, with 1 pending matter. Because no examiner accounts for more than the recorded individual matter, docket management should address each assignment separately and preserve application-specific response strategies.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (25%) |
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAVIS, BRIAN J | 1 | 84.8% | -3.9% |
| HELM, CARALYNNE E | 1 | 28.9% | +49.8% |
| HOERNER, PAUL ELLSWORTH | 1 | 50.6% | +62.3% |
| WANG, CHANG YU | 1 | 33.4% | +53.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18833889 | NUCLEIC ACID ENCODED TRANSCRIPTION FACTOR INHIBITORS | DAVIS, BRIAN J | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18256277 | COMPOSITIONS AND METHODS FOR MUCOSAL DRUG DELIVERY | HELM, CARALYNNE E | — |
| 18312848 | Electrospun Reinforced Suturable Artificial Cornea and Uses Thereof | HOERNER, PAUL ELLSWORTH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18256277 | COMPOSITIONS AND METHODS FOR MUCOSAL DRUG DELIVERY | HELM, CARALYNNE E | — |
| 18312848 | Electrospun Reinforced Suturable Artificial Cornea and Uses Thereof | HOERNER, PAUL ELLSWORTH | — |
| 16609184 | METHODS AND COMPOSITIONS FOR REDUCING CORNEAL ENDOTHELIAL CELL LOSS | WANG, CHANG YU | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| 1615 | 1 |
| 3774 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18833889 | NUCLEIC ACID ENCODED TRANSCRIPTION FACTOR INHIBITORS | DAVIS, BRIAN J | 1614 | §112 | Final Rejection | — | Pending | Jul 27, 2024 |
| 18256277 | COMPOSITIONS AND METHODS FOR MUCOSAL DRUG DELIVERY | HELM, CARALYNNE E | 1615 | §103§112 | Final Rejection | — | Pending | Jun 07, 2023 |
| 18312848 | Electrospun Reinforced Suturable Artificial Cornea and Uses Thereof | HOERNER, PAUL ELLSWORTH | 3774 | §102§103§112 | Non-Final OA | — | Pending | May 05, 2023 |
| 16609184 | METHODS AND COMPOSITIONS FOR REDUCING CORNEAL ENDOTHELIAL CELL LOSS | WANG, CHANG YU | 1675 | §102 | Non-Final OA | — | Pending | Oct 28, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe Schepens Eye Research Institute Inc. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Brian J Davis has the most, with 1 of The Schepens Eye Research Institute Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
